Sign In
Buy BHVN
$13.50
-0.320 (-2.32%)
At Close: Jul 31, 2026
Why Biohaven Stock Is Skyrocketing Today
12:00pm, Wednesday, 27'th Sep 2023
Biohaven released a new investor presentation that featured encouraging information about drug candidate BHV-1300. The experimental drug showed promise in treating autoimmune diseases.
Why Biohaven Stock Is Crashing Today
12:50pm, Thursday, 27'th Jul 2023
The FDA refused to review Biohaven's filing for approval of troriluzole in treating an ultrarare disease. Biohaven still hopes to convince the agency of the merits of its data on the experimental drug
2 Growth Stocks With Major Incoming Catalysts
05:31am, Tuesday, 27'th Jun 2023
BridgeBio stock collapsed when acoramidis failed a pivotal trial, but follow-up data on the way could allow the program, and the stock, to redeem itself. Biohaven shares could shoot higher if the U.S.
Why Biohaven Stock Caught Fire This Week
09:11am, Friday, 02'nd Jun 2023
Wednesday, Biohaven held a research and development day presentation for investors. With the company making progress on several fronts, investors appear to be optimistic about its post-buyout future.
Biohaven (BHVN) Stock up 8% on Encouraging Pipeline Updates
12:36pm, Thursday, 01'st Jun 2023
At its R&D Day, Biohaven (BHVN) provides updates on its pipeline. It also announced submission of a regulatory filing seeking approval for troriluzole in SCA3, an ultra-rare disorder.
Is Biohaven Ltd. (BHVN) Stock Outpacing Its Medical Peers This Year?
11:23am, Thursday, 30'th Mar 2023
Here is how Biohaven Ltd. (BHVN) and Hologic (HOLX) have performed compared to their sector so far this year.
Biohaven (BHVN) Acquires Dual Inhibitor for Brain Disorders
12:13pm, Thursday, 23'rd Mar 2023
Biohaven (BHVN) has acquired an exclusive license for dual Inhibitor of TYK2/JAK1 for the pre-clinical study of immune-mediated brain disorders.
Biohaven: Spun And Done - Time To Exit
05:06pm, Thursday, 09'th Mar 2023
Biohaven is on the far side of its spin cycle and faces the world as a much diminished company. Biohaven has upcoming catalysts, but they are either early stage or have serious question marks.
Here's What's Next For Biohaven After Its $12 Billion Pfizer Buyout, According To CEO Vlad Coric
12:52pm, Thursday, 02'nd Feb 2023
Biohaven is taking the same tact that led to a nearly $12 billion Pfizer buyout with the rest of its pipeline — and BHVN stock has soared. The post Here's What's Next For Biohaven After Its $12 Bill
These Are the Top 10 Holdings of Paul Tudor Jones
10:55pm, Tuesday, 10'th Jan 2023
Paul Tudor Jones is one of the most respected names in the hedge fund industry.
Biohaven to Present at the 41st Annual J.P. Morgan Healthcare Conference
07:30am, Friday, 06'th Jan 2023
NEW HAVEN, Conn. , Jan. 6, 2023 /PRNewswire/ -- Biohaven Ltd.
Is Biohaven Ltd. (BHVN) Outperforming Other Medical Stocks This Year?
11:17am, Thursday, 05'th Jan 2023
Here is how Biohaven Ltd. (BHVN) and Clover Health Investments, Corp. (CLOV) have performed compared to their sector so far this year.
After Plunging 13% in 4 Weeks, Here's Why the Trend Might Reverse for Biohaven Ltd. (BHVN)
11:17am, Tuesday, 29'th Nov 2022
Biohaven Ltd. (BHVN) is technically in oversold territory now, so the heavy selling pressure might have exhausted.
Biohaven CEO on 'monumental approval' of migraine drug
05:40am, Saturday, 19'th Nov 2022
"We can now say you know that Nurtec ODT is approved for the preventative treatment of migraine," Biohaven CEO Vlad Coric said.
Biohaven Ltd. (BHVN) Surges 7.6%: Is This an Indication of Further Gains?
04:31am, Friday, 07'th Oct 2022
Biohaven Ltd. (BHVN) witnessed a jump in share price last session on above-average trading volume.
